Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.

Tveit MC, Gelfand ST, Simon JA.

Open source

DOI
10.1093/jsxmed/qdae182
Published
2025-01-01
Container
J Sex Med
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/jsxmed/qdae182,
  title = {Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.},
  author = {Tveit MC and  Gelfand ST and  Simon JA.},
  year = {2025},
  journal = {J Sex Med},
  doi = {10.1093/jsxmed/qdae182},
  url = {https://doi.org/10.1093/jsxmed/qdae182}
}

RIS

TY  - JOUR
TI  - Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.
AU  - Tveit MC
AU  -  Gelfand ST
AU  -  Simon JA.
PY  - 2025
JO  - J Sex Med
DO  - 10.1093/jsxmed/qdae182
UR  - https://doi.org/10.1093/jsxmed/qdae182
ER  - 

APA

MC, T., ST, G., & JA., S. (2025). Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.. J Sex Med. https://doi.org/10.1093/jsxmed/qdae182

Source records